1 / 47

Towards universal access: scaling up priority HIV/AIDS interventions in the health sector

Towards universal access: scaling up priority HIV/AIDS interventions in the health sector. Progress report 2009 Slide set – six summary data slides and all 40 figures from the report.

ena
Download Presentation

Towards universal access: scaling up priority HIV/AIDS interventions in the health sector

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Towards universal access: scaling up priority HIV/AIDS interventions in the health sector Progress report 2009 Slide set – six summary data slides and all 40 figures from the report

  2. Increase in antiretroviral therapy in low- and middle-income countries, adults and children [combined], December 2007–December 2008

  3. Antiretroviral therapy coverage in low- and middle-income countries, adults and children [combined], December 2008

  4. Antiretroviral therapy coverage in low- and middle-income countries, adults (≥15 years), December 2008

  5. Antiretroviral therapy coverage in low- and middle-income countries, children (0–14 years), December 2008

  6. Prevention of mother-to-child transmission coverage in low- and middle-income countries, December 2008

  7. Number of people receiving antiretroviral therapy in low- and middle-income countries, by region, 2002–2008

  8. Fig. 2.1. Transaction volumes of rapid HIV tests, 2004–2008

  9. Fig. 2.2. Reported number of health facilities providing HIV testing and counselling services in low- and middle-income countries with comparable data, by region, 2007 and 2008

  10. Fig. 2.3. Percentage of women with HIV testing and counselling and percentage of women with secondary or higher education, district comprehensive assessment districts in Burkina Faso, Haiti and Zambia, 2008

  11. Fig. 2.4. Percentage of women and men receiving an HIV test and test results in the 12 months preceding the survey in countries with repeat population surveys, 2003–2008

  12. Fig. 2.5. Percentage of women and men (≥15 years) who had ever received an HIV test and test results, South Africa, 2002, 2005 and 2008

  13. Fig. 3.1. Situation analysis of harm reduction interventions in the Middle East and North Africa at baseline, 2008

  14. Fig. 3.2. Blood donation per 1000 population, 2007

  15. Fig. 4.1. Number of people receiving antiretroviral therapy in low- and middle-income countries, by region, 2002–2008

  16. Fig. 4.2. Measuring attrition from antiretroviral therapy programmes

  17. Fig. 4.3. Retention on antiretroviral therapy at 12 months after initiation of treatment in 61 low- and middle-income countries by region, 2008

  18. Fig. 4.4. 12-month retention of people receiving antiretroviral therapy in selected treatment sites, Papua New Guinea, 2008

  19. Fig. 4.5. Trends in retention on antiretroviral therapy in low- and middle-income countries by region, 2008

  20. Fig. 4.6. Trends over time in the median CD4 count at baseline count of 36 715 adults starting antiretroviral therapy between 2001 and 2006

  21. Fig. 4.7. Antiretroviral therapy coverage and all-cause mortality in South Africa, 2003–2006

  22. Fig. 4.8. Countries implementing at least one element of the WHO Global Strategy for the Prevention and Assessment of HIV Drug Resistance and locations of HIV drug resistance testing laboratories, February 2009

  23. Fig. 4.9. Main first-line antiretroviral regimens used among 2.4 million adults in 36 low- and middle-income countries, December 2008

  24. Fig. 4.10. Main second-line antiretroviral regimens used among adults (n=51 135) in 36 low- and middle-income countries, December 2008

  25. Fig. 4.11. First-line regimens used among children (n=177 064) in 36 low- and middle-income countries, December 2008

  26. Fig. 4.12. Second-line regimens used among children (n=5997) in 35 low- and middle-income countries, December 2008

  27. Fig. 4.13. Median annual cost (in US dollars) of first-line antiretroviral drug regimens in low-income countries by year, 2004–2008

  28. Fig. 4.14. Median annual cost (in US dollars) of first-line antiretroviral drug regimens in lower-middle-income countries by year, 2004–2008

  29. Fig. 4.15. Median price (in US dollars) of first-line antiretroviral drug regimens in upper-middle-income countries by year, 2004–2008

  30. Fig. 4.16. Estimated HIV prevalence (%) among people newly infected with TB, 2007

  31. Fig. 4.17. Rates of HIV testing among people with TB in countries in sub-Saharan Africa, 2004–2007

  32. Fig. 5.1. Number of low- and middle-income countries with national scale-up plans including population-based targets for preventing mother-to-child transmission and for HIV care and treatment for children, by region, 2008

  33. Fig. 5.2. Percentage of women and men aged 15–49 years with comprehensive knowledgea of HIV in countries with recent population-based surveys (2007–2008)

  34. Fig. 5.3. Reported percentage condom use at last sexual intercourse among women 15–49 years old who had sex in the past year by five-year age groups in selected population-based surveys, 2005–2007

  35. Fig. 5.4. Unmet need for family planning among married women 15–49 years old (%) in countries with a generalized epidemic, 2006–2008

  36. Fig. 5.5. Percentage of pregnant women who received an HIV test in low- and middle-income countries by region, 2004–2008a

  37. Fig. 5.6. Percentage of pregnant women who received an HIV test in Malawi, 2004–2008

  38. Fig. 5.7. Percentage of pregnant women with HIV receiving antiretrovirals for preventing mother-to-child transmission of HIV in low- and middle-income countries by region, 2004–2008

  39. Fig. 5.8. Percentage of pregnant women living with HIV who received antiretrovirals to prevent mother-to-child transmission of HIV in Côte d’Ivoire, 2005–2008

  40. Fig. 5.9. Percentage of pregnant women living with HIV receiving antiretrovirals to prevent the mother-to-child transmission of HIV in 20 countries with the highest HIV disease burden among pregnant women (in descending order), 2008

  41. Fig. 5.10. Coverage of antiretrovirals to prevent the mother-to-child transmission of HIV, 2008

  42. Fig. 5.11. Percentage distribution of various antiretroviral regimens provided to pregnant women in low- and medium-income countries in 2007 and 2008, based on available data

  43. Fig. 5.12. Contribution of the 20 countries with the largest numbers of women needing antiretrovirals for preventing the mother-to-child transmission of HIV to the global gap to reach 80% of those in need, 2008

  44. Fig. 5.13. Coverage of antiretroviral prophylaxis among infants born to mothers living with HIV in low- and middle-income countries by region, 2008

  45. Fig. 5.14. Percentage of pregnant women living with HIV and infants born to them who received antiretrovirals for preventing mother-to-child transmission, 2004–2008

  46. Fig. 5.15. Average age of infants at their first HIV DNA test in Namibia in weeks, 2006–2008

  47. Fig. 5.16. Percentage of children receiving antiretroviral therapy in low- and middle-income countries, 2005–2008

More Related